Main menu


Boehringer Ingelheim records a positive performance in 2020, with investments amounting to 3.7 billion euros in research and development

Significant commitment to research and development to create treatments for SARS-Cove-2

- The total volume of the company's investments in research and development increased by 7%, to reach 3.7 billion euros

Boehringer Ingelheim ranks second as the fastest growing pharmaceutical company among the top 25 pharmaceutical companies in the region in 2020

11% growth in the gross net of sales of human pharmaceuticals and veterinary health in the Middle East, Turkey and Africa region during the year 2020

- "Boehringer Ingelheim" Egypt launched an awareness campaign entitled "For your diabetes and the health of your heart", whereby the Cairo Tower was lit on World Diabetes Day in order to enhance awareness of the disease.


Boehringer Ingelheim continued to significantly increase its investment in research and development during the year 2020, seeking to launch innovative drugs and treatments for diseases for which there are insufficiently successful treatments. Specifically, the company has stepped up its research efforts aimed at finding potential treatments related to the Covid-19 pandemic, as it spent 3.7 billion euros on research and development, an increase of 7% compared to the previous year. This number represents the largest annual investment in research and development in the history of the research-based biopharmaceutical company in nearly 136 years.

For his part, Dr. Mohamed Musharraf, General Manager at Boehringer Ingelheim Egypt, said: “Boehringer Ingelheim continues its relentless efforts based on its strong vision towards improving human and veterinary health. The Egyptian market, and as we are the first headquarters for the company's operations in the region, we have been keen to accelerate the availability of innovative medical treatments and solutions throughout the regions of the Republic, and we will certainly continue these relentless endeavors for years to come. Successful campaigns and initiatives aimed at raising awareness among local communities, which included the campaign "For your sugar and your heart health" to raise awareness of type 2 diabetes and stroke campaigns, in addition to the "Angels" initiative that aims to provide necessary and effective medical care to stroke patients. We have pursued our goal of ensuring that our pharmaceutical products are accessible to patients in all parts of the country. "

Based on the company's vast experience in various fields of treatment such as respiratory diseases and virology, the company is involved in several projects aimed at finding medical solutions to treat Covid-19. In December 2020, Boehringer Ingelheim, University Hospital Cologne, University of Marburg and German Center for Infection Research announced the launch of the first and second phase clinical trials of the drug BI 767551, which neutralizes antibodies to the SARS-Cove virus. 2, and it may become a new treatment and preventive option to reduce the risks and potential effects of Covid-19 infection. Other initiatives related to the COVID-19 pandemic include: research and development on SARS-CoV-2 antibodies that are able to neutralize the virus; Small particles that prevent its reproduction; To develop a treatment to prevent micrometal clots in the blood (thromboembolism).

Strong performance despite the COVID-19 pandemic

Despite the comprehensive repercussions imposed by the Covid-19 pandemic, the company recorded net sales of 19.57 billion euros, a growth of 3% compared to the previous year. In the Middle East, Turkey and Africa region in particular, Boehringer Ingelheim's business witnessed remarkable growth, as the company recorded a total net sales of 515 million euros, an increase of 11% compared to 2019, and a net sales of 383 million euros and 132 million euros for the human pharmaceutical sector. And veterinary health, respectively, with an increase of 20% during 2020.

Thanks to the company's great efforts in the Middle East, Turkey and Africa, the company ranked second as the fastest growing pharmaceutical company among the top 25 pharmaceutical companies in the region during 2020, and ranked 14th among the top 25 multinational pharmaceutical companies as well, and its business recorded an overall growth in the field of human medicines. By 20% in the Middle East, Turkey and Africa.

Human pharmaceutical drugs - strong growth in various regions

Net sales of human pharmaceutical drugs recorded a strong growth of 5.8% compared to the previous year, to reach 14.42 billion euros, adjusted for currency exchange rates, standing behind 74% of total net sales. The company achieved strong pharmaceutical sales performance in all regions, including the Middle East, Turkey and Africa

Treatments for cardiovascular disease, metabolic diseases, and respiratory diseases remain the main contributors to the company's net sales worldwide. For example, the diabetes drug used to lower blood sugar in adults with type 2 diabetes is the largest contributor to the company's human pharmaceutical revenue.

For the first time, Boehringer Ingelheim's pulmonary fibrosis treatment recorded the second strongest revenue contribution, and the drug is used to treat patients with idiopathic pulmonary fibrosis and interstitial lung disease related to systemic sclerosis. In some countries, this drug is used to treat chronic fibrosis of other interstitial lung diseases with an advanced phenotype.

Veterinary health - a strong performer in a competitive market

The Veterinary Health Unit in Boehringer Ingelheim is one of the world's largest providers of vaccines and veterinary medicines, with a strong presence in the livestock and pet sectors. During 2020, the unit performed strongly in a highly competitive market, registering 5% growth (compared to the previous year, adjusted for currency exchange), bringing its net sales to 4.12 billion euros. In particular, the company's pet anti-parasite product categories have been successful beyond expectations. The anti-parasite NEXGARD maintained its position as the company's best-selling product, achieving a growth of 12% (compared to the previous year, adjusted for the currency exchange rate), with net sales reaching 804 million euros.

According to data issued by the international non-profit CEESA Association, Boehringer Ingelheim Egypt ranked second in terms of the total share in the local market thanks to the company's innovative and effective solutions for bird and livestock health, general veterinary treatments and pet health across Egypt. This includes the provision of vaccines, pharmaceuticals, parasiticides, and nutritional supplements.

In addition, Boehringer Ingelheim climbed its second ranking on the global Medicines Access Index 2021, which is published every two years, moving up two places to be ranked 12th among the 20 largest pharmaceutical companies in the world thanks to its continuous efforts to overcome barriers to access to care. Health, especially in needy communities in low- to middle-income countries.

Boehringer Ingelheim Egypt launched a diabetes awareness campaign entitled "For your sugar and your heart health". In the context of enhancing awareness of the disease, the Cairo Tower was lit during the World Diabetes Day in November 2020, as an expression of support for people with this disease in various parts of the Republic. In September 2020, the company launched the "Angels" initiative, which included several university hospitals across Egypt and provided educational programs to train and educate physicians' medical caregivers on stroke case management. This initiative was launched in cooperation with the Supreme Council of Universities and the Egyptian Society of Neurology, Psychiatry and Neurosurgery, and included online medical lectures by leading specialists and experts in the field of stroke management, diagnosis and treatment. The program is accredited by the European Stroke Federation and the American Continuing Medical Education Association.

Tucson Company Inc It is one of the best Egyptian companies specialized in the field of creating and developing Android applications and games, selling them to others, and publishing them through all the services of publishing free and paid applications and games